Loading stock data…
RPRX
$57.09+0.86 (+1.53%)
Market ClosedLast close Jun 29
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Royalty Pharma plc in the Healthcare sector is trading at $57.09 with a market capitalization of $31.2B. Wall Street consensus targets $59.25 (8 analysts), implying a +3.8% move over the next 12 months. The stock is currently near its 52-week high of $57.17, remaining 30.9% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $630.58M↑ | $621.99M↑ | $609.29M↑ | $578.66M↑ | $568.25M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $632.48M↑ | $388.38M↓ | $427.16M↑ | $209.80M↓ | $534.18M |
| Net Income | $294.69M↑ | $214.21M↓ | $288.22M↑ | $30.18M↓ | $239.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-sta...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$31.18B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.19%
ROE
Average efficiency. Growth may require heavy reinvestment.
12.01%
Volume
Today's trading volume
2.46M
Recent News
Royalty Pharma, plc (RPRX) Rallied on Earnings Beat
Meridian Funds, managed by ArrowMark Partners, released its first-quarter 2026 investor letter for “Meridian Hedged Equity Fund”. A copy of the letter can be downloaded here. The Fund invests in high-quality growth companies and mitigates risk by writing call options. Following the late-February strike on Iran, oil prices surged, leading to a risk-off sentiment, boosting […]
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (NASDAQ:RPRX) and its peers.
This Royalty Pharma Insider Reduced Their Stake By 10%
Insiders were net sellers of Royalty Pharma plc's ( NASDAQ:RPRX ) stock during the past year. That is, insiders sold...
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Why Is Agenus (AGEN) Down 9.6% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.